KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Revenue (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Revenue for 13 consecutive years, with $254.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 240.36% year-over-year to $254.5 million, compared with a TTM value of $490.7 million through Dec 2025, up 110.45%, and an annual FY2025 reading of $490.7 million, up 110.45% over the prior year.
  • Revenue was $254.5 million for Q4 2025 at Travere Therapeutics, up from $40.0 million in the prior quarter.
  • Across five years, Revenue topped out at $254.5 million in Q4 2025 and bottomed at -$158.2 million in Q4 2021.
  • Average Revenue over 5 years is $48.9 million, with a median of $43.2 million recorded in 2023.
  • The sharpest move saw Revenue tumbled 410.38% in 2021, then surged 240.36% in 2025.
  • Year by year, Revenue stood at -$158.2 million in 2021, then surged by 118.54% to $29.3 million in 2022, then soared by 53.58% to $45.1 million in 2023, then skyrocketed by 65.98% to $74.8 million in 2024, then soared by 240.36% to $254.5 million in 2025.
  • Business Quant data shows Revenue for TVTX at $254.5 million in Q4 2025, $40.0 million in Q3 2025, and $114.4 million in Q2 2025.